BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15269607)

  • 1. Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.
    Leonard GD; Wagner MR; Quinn MG; Grem JL
    Anticancer Drugs; 2004 Aug; 15(7):733-5. PubMed ID: 15269607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine combined with oxaliplatin (CAPOX) in clinical practice: how significant is peripheral neuropathy?
    Arkenau HK
    Ann Oncol; 2011 Jan; 22(1):239-240. PubMed ID: 21169475
    [No Abstract]   [Full Text] [Related]  

  • 3. [The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
    Ishii K; Kanamoto A; Miyanaga S; Noto M; Takeda T; Tani T; Yagi M
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):319-22. PubMed ID: 25812500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Bölke E; Peiper M; Budach W
    N Engl J Med; 2008 May; 358(18):1965; author reply 1965. PubMed ID: 18450611
    [No Abstract]   [Full Text] [Related]  

  • 6. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
    Leone F; Artale S; Marino D; Cagnazzo C; Cascinu S; Pinto C; Fornarini G; Tampellini M; Di Fabio F; Sartore-Bianchi A; De Carlis L; Pugliese R; Capussotti L; Gioeni L; Siena S; Aglietta M
    Cancer; 2013 Oct; 119(19):3429-35. PubMed ID: 23868516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
    Sumpter K; Harper-Wynne C; Cunningham D; Gillbanks A; Norman AR; Hill M
    Clin Oncol (R Coll Radiol); 2003 Aug; 15(5):221-6. PubMed ID: 12924449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A; Gallego-Plazas J; Guillén-Ponce C
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
    Hill A; Bergin P; Hanning F; Thompson P; Findlay M; Damianovich D; McKeage MJ
    BMC Cancer; 2010 Aug; 10():451. PubMed ID: 20731872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
    Matsuda C; Honda M; Tanaka C; Fukunaga M; Ishibashi K; Munemoto Y; Hata T; Bando H; Oshiro M; Kobayashi M; Tokunaga Y; Fujii A; Nagata N; Oba K; Mishima H
    Int J Clin Oncol; 2016 Jun; 21(3):566-72. PubMed ID: 26475356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute oxaliplatin-induced peripheral nerve hyperexcitability.
    Wilson RH; Lehky T; Thomas RR; Quinn MG; Floeter MK; Grem JL
    J Clin Oncol; 2002 Apr; 20(7):1767-74. PubMed ID: 11919233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
    Borner MM; Dietrich D; Stupp R; Morant R; Honegger H; Wernli M; Herrmann R; Pestalozzi BC; Saletti P; Hanselmann S; Müller S; Brauchli P; Castiglione-Gertsch M; Goldhirsch A; Roth AD
    J Clin Oncol; 2002 Apr; 20(7):1759-66. PubMed ID: 11919232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.